Skip to main content
Journal cover image

A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.

Publication ,  Journal Article
Johnson, DH; Ruckdeschel, JC; Keller, JH; Lyman, GH; Kallas, GJ; Macdonald, J; DeConti, RC; Lee, J; Ringenberg, QS; Patterson, WP
Published in: Cancer
January 1, 1991

In a randomized multi-center study, 83 patients with small cell lung cancer were randomly assigned to treatment with cisplatin 100 mg/m2 intravenously (IV) day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3 or cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV day 1 and 240 mg/m2 orally days 2 and 3. Both regimens were repeated every 4 weeks. Prior to randomization, patients were stratified by extent of disease, performance status, and gender. A total of 41 patients were randomly assigned to the parenteral treatment only regimen, and 42 patients received cisplatin and IV/oral etoposide therapy. Both treatment arms were comparable regarding patient characteristics. Limited disease (LD) patients constituted 52% and 49% of the patient population for the oral and IV etoposide regimens, respectively. The overall complete response (CR) and partial response (PR) rate was 50% (95% confidence interval [CI] 35% to 65%) for the oral etoposide regimen and 59% (95% CI 44% to 74%) for the IV etoposide regimen (P = 0.438). For both regimens, 55% of the LD patients achieved either CR or PR. Time to progression and survival were comparable for both treatment arms. Hematologic toxicity was comparable in both treatment arms, with 80% of patients experiencing grade 3 or 4 neutropenia or thrombocytopenia. Moderate to severe anemia and weight loss were more predominant with the IV than with the oral regimen.

Duke Scholars

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

January 1, 1991

Volume

67

Issue

1 Suppl

Start / End Page

245 / 249

Location

United States

Related Subject Headings

  • Remission Induction
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Injections, Intravenous
  • Humans
  • Female
  • Etoposide
  • Drug Administration Schedule
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Johnson, D. H., Ruckdeschel, J. C., Keller, J. H., Lyman, G. H., Kallas, G. J., Macdonald, J., … Patterson, W. P. (1991). A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. Cancer, 67(1 Suppl), 245–249. https://doi.org/10.1002/1097-0142(19910101)67:1+<245::aid-cncr2820671306>3.0.co;2-z
Johnson, D. H., J. C. Ruckdeschel, J. H. Keller, G. H. Lyman, G. J. Kallas, J. Macdonald, R. C. DeConti, J. Lee, Q. S. Ringenberg, and W. P. Patterson. “A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.Cancer 67, no. 1 Suppl (January 1, 1991): 245–49. https://doi.org/10.1002/1097-0142(19910101)67:1+<245::aid-cncr2820671306>3.0.co;2-z.
Johnson DH, Ruckdeschel JC, Keller JH, Lyman GH, Kallas GJ, Macdonald J, et al. A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. Cancer. 1991 Jan 1;67(1 Suppl):245–9.
Johnson, D. H., et al. “A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.Cancer, vol. 67, no. 1 Suppl, Jan. 1991, pp. 245–49. Pubmed, doi:10.1002/1097-0142(19910101)67:1+<245::aid-cncr2820671306>3.0.co;2-z.
Johnson DH, Ruckdeschel JC, Keller JH, Lyman GH, Kallas GJ, Macdonald J, DeConti RC, Lee J, Ringenberg QS, Patterson WP. A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. Cancer. 1991 Jan 1;67(1 Suppl):245–249.
Journal cover image

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

January 1, 1991

Volume

67

Issue

1 Suppl

Start / End Page

245 / 249

Location

United States

Related Subject Headings

  • Remission Induction
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Injections, Intravenous
  • Humans
  • Female
  • Etoposide
  • Drug Administration Schedule